RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components

Histopathology

Volumn 57, Issue 3, 2010, Pages 444-450

  Mochizuki, Kunio ^a   Kondo, Tetsuo ^a   Nakazawa, Tadao ^a   Iwashina, Masanori ^b   Kawasaki, Tomonori ^a   Nakamura, Nobuki ^c   Yamane, Tetsu ^a   Murata, Shin Ichi ^d   Ito, Koichi ^e   Kameyama, Kaori ^f   Kobayashi, Makio ^g   Katoh, Ryohei ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b Nishigunma National Hospital   (Germany)

^c TOKYO MEDICAL UNIVERSITY   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

^e ITO HOSPITAL   (Japan)

^f KEIO UNIVERSITY HOSPITAL   (Japan)

^g TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

anaplastic transformation; BRAF mutation; papillary thyroid carcinoma; RET rearrangements; undifferentiated thyroid carcinoma

Indexed keywords

B RAF KINASE; PROTEIN RET;

ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; GENE MUTATION; GENE REARRANGEMENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALIGNANT TRANSFORMATION; PREVALENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SEQUENCE ANALYSIS; THYROID PAPILLARY CARCINOMA; TUMOR DIFFERENTIATION; UNDIFFERENTIATED CARCINOMA;

BASE SEQUENCE; CARCINOMA; CARCINOMA, PAPILLARY; CELL DIFFERENTIATION; CHROMOSOME ABERRATIONS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-RET; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THYROID NEOPLASMS;

EID: 77956629969     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03646.x     Document Type: Article

References (40)

1. DeLellis RA, Williams ED, LiVolsi VA et al. Tumours of the thyroid and parathyroid. In DeLellis RA, Lloyd RV, Heitz PU, Eng C eds. Pathology and genetics. Tumours of endocrine organs. Lyon, France: IARC Press, 2003 49 133.
2. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer 2006 6 292 306.
3. Lam KY, Lo CY, Chan KW et al. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann. Surg. 2000 231 329 338.
4. Lo CY, Lam KY, Wan KY. Anaplastic carcinoma of the thyroid. Am. J. Surg. 1999 177 337 339.
5. Nikiforov YE. RET/PTC rearrangement in thyroid tumors. Endocr. Pathol. 2002 13 3 16.
6. Nakazawa T, Kondo T, Kobayashi Y et al. RET gene rearrangements (RET/PTC1 and RET/PTC3) in papillary thyroid carcinomas from an iodine-rich country (Japan). Cancer 2005 104 943 951.
7. Ishizaka Y, Kobayashi S, Ushijima T, Hirohashi S, Sugimura T, Nagao M. Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene 1991 6 1667 1672.
8. Tallini G, Santoro M, Helie M et al. RET/PTC oncogene activation defines a subset of papillary carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin. Cancer Res. 1998 4 287 294.
9. Motomura T, Nikiforov YE, Namba H et al. RET rearrangements in Japanese pediatric and adult papillary thyroid cancers. Thyroid 1998 8 485 489.
10. Papotti M, Volante M, Giuliano A et al. RET/PTC activation in hyalinizing trabecular tumors of the thyroid. Am. J. Surg. Pathol. 2000 24 1615 1621.
11. Cheung CC, Boerner SL, MacMillan CM, Ramyar L, Asa SL. Hyalinizing trabecular tumor of the thyroid: a variant of papillary carcinoma proved by molecular genetics. Am. J. Surg. Pathol. 2000 24 1622 1626.
12. Wirtschafter A, Schmidt R, Rosen D et al. Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis. Laryngoscope 1997 107 95 100.
13. Sheils OM, O'eary JJ, Uhlmann V, Lattich K, Sweeney EC. RET/PTC-1 Activation in Hashimoto thyroiditis. Int. J. Surg. Pathol. 2000 8 185 189.
14. Bounacer A, Wicker R, Caillou B et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene 1997 15 1263 1273.
15. Elisei R, Romei C, Vorontsova T et al. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J. Clin. Endocrinol. Metab. 2001 86 3211 3216.
16. Santoro M, Carlomagno F, Hay ID et al. Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J. Clin. Invest. 1992 89 1517 1522.
17. Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer 2005 103 2261 2268.
18. Nikiforov YE. Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas. Endoc. Pathol. 2004 15 319 327.
19. Sobrinho-Simoes M, Preto A, Rocha AS et al. Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch. 2005 447 787 793.
20. Sedliarou I, Saenko V, Lantsov D et al. The BRAFT1796A transversion is a prevalent mutational event in human thyroid microcarcinoma. Int. J. Oncol. 2004 25 1729 1735.
21. Nikiforova MN, Kimura ET, Gandhi M et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J. Clin. Endocrinol. Metab. 2003 88 5399 5404.
22. Begum S, Rosenbaum E, Henrique R, Cohen Y, Sidransky D, Westra WH. BRAF mutations in anaplastic thyroid carcinoma: implications for tumor origin, diagnosis and treatment. Mod. Pathol. 2004 17 1359 1363.
23. Xing M, Vasko V, Tallini G et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J. Clin. Endocrinol. Metab. 2004 89 1365 1368.
24. Fukushima T, Suzuki S, Mashiko M et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene 2003 22 6455 6457.
25. Namba H, Nakashima M, Hayashi T et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J. Clin. Endocrinol. Metab. 2003 88 4393 4397.
26. Cohen Y, Rosenbaum E, Clark DP et al. Mutational analysis of BRAF in fine needle aspiration biopsies of the thyroid: a potential application for the preoperative assessment of thyroid nodules. Clin. Cancer Res. 2004 10 2761 2765.
27. Fugazzola L, Mannavola D, Cirello V et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin. Endocrinol. (Oxf.) 2004 61 239 243.
28. Puxeddu E, Moretti S, Elisei R et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 2004 89 2414 2420.
29. Soares P, Trovisco V, Rocha AS et al. BRAF mutations typical of papillary thyroid carcinoma are more frequently detected in undifferentiated than in insular and insular-like poorly differentiated carcinomas. Virchows Arch. 2004 444 572 576.
30. Hayashida N, Namba H, Kumagai A et al. A rapid and simple detection method for the BRAF(T1796A) mutation in fine-needle aspirated thyroid carcinoma cells. Thyroid 2004 14 910 915.
31. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003 63 1454 1457.
32. Cohen Y, Xing M, Mambo E et al. BRAF mutation in papillary thyroid carcinoma. J. Natl Cancer Inst. 2003 95 625 627.
33. Soares P, Trovisco V, Rocha AS et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003 22 4578 4580.
34. Xing M, Cohen Y, Mambo E et al. Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis. Cancer Res. 2004 64 1664 1668.
35. Xing M, Tufano RP, Tufaro AP et al. Detection of BRAF mutation on fine needle aspiration biopsy specimens: a new diagnostic tool for papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2004 89 2867 2872.
36. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med. J. 2004 45 818 821.
37. Perren A, Schmid S, Locher T et al. BRAF and endocrine tumors: mutations are frequent in papillary thyroid carcinomas, rare in endocrine tumors of the gastrointestinal tract and not detected in other endocrine tumors. Endocr. Relat. Cancer 2004 11 855 860.
38. Porra V, Ferraro-Peyret C, Durand C et al. Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J. Clin. Endocrinol. Metab. 2005 90 3028 3035.
39. Kondo T, Nakazawa T, Murata S et al. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum. Pathol. 2007 38 1810 1818.
40. Vasko V, Hu S, Wu G et al. High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J. Clin. Endocrinol. Metab. 2005 90 5265 5269.